Clin Orthop Surg.  2016 Mar;8(1):1-8. 10.4055/cios.2016.8.1.1.

Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress

Affiliations
  • 1Department of Orthopaedic Surgery, University Paris East (UPEC), Hopital Henri Mondor, Creteil, France. philippe.hernigou@wanadoo.fr
  • 2EFS Cell Therapy Facility, University Paris East (UPEC), Hopital Henri Mondor, Creteil, France.

Abstract

Avascular necrosis of the femoral head is caused by a multitude of etiologic factors and is associated with collapse with a risk of hip arthroplasty in younger populations. A focus on early disease management with the use of stem cells was proposed as early as 1985 by the senior author (PH). We undertook a systematic review of the medical literature to examine the progress in cell therapy during the last 30 years for the treatment of early stage osteonecrosis.

Keyword

Hip; Osteonecrosis; Cell therapy; Mesenchymal stromal cells; Tissue engineering

MeSH Terms

*Cell- and Tissue-Based Therapy
Femur Head/*surgery
Femur Head Necrosis/*surgery
Humans
*Mesenchymal Stem Cell Transplantation
*Tissue Engineering

Cited by  1 articles

Mesenchymal Stem Cell Therapy for Bone Regeneration
Yuan-Zhe Jin, Jae Hyup Lee
Clin Orthop Surg. 2018;10(3):271-278.    doi: 10.4055/cios.2018.10.3.271.


Reference

1. Hernigou P, Beaujean F. La moelle osseuse, une cle dans la comprehension des necroses de hanche idiopathiques. Rev Rhum Mal Osteoartic. 1993; 60(10):722.
2. Hernigou P, Beaujean F. Bone marrow activity in the upper femoral extremity in avascular osteonecrosis. Rev Rhum Engl Ed. 1993; 60(1):610.
3. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002; (405):14–23.
Article
4. Hernigou P, Beaujean F. Abnormalities in the bone marrow of the iliac crest in patients who have osteonecrosis secondary to corticosteroid therapy or alcohol abuse. J Bone Joint Surg Am. 1997; 79(7):1047–1053.
Article
5. Hernigou P, Beaujean F, Lambotte JC. Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br. 1999; 81(2):349–355.
Article
6. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966; 16(3):381–390.
Article
7. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells. 2001; 19(3):180–192.
Article
8. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001; 49(3):507–521.
Article
9. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013; 45:e54.
Article
10. Hernigou P. Bone transplantation and tissue engineering, part IV. Mesenchymal stem cells: history in orthopedic surgery from Cohnheim and Goujon to the Nobel Prize of Yamanaka. Int Orthop. 2015; 39(4):807–817.
Article
11. Hernigou P, Manicom O, Poignard A, Nogier A, Filippini P, De Abreu L. Core decompression with marrow stem cells. Oper Tech Orthop. 2004; 14(2):68–74.
Article
12. Hernigou P, Zilber S, Filippini P, Rouard H, Mathieu G, Poignard A. Bone marrow injection in hip osteonecrosis. Tech Orthop. 2008; 23(1):18–25.
Article
13. Hernigou P, Homma Y, Flouzat Lachaniette CH, et al. Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells. Int Orthop. 2013; 37(11):2279–2287.
Article
14. Hernigou J, Picard L, Alves A, Silvera J, Homma Y, Hernigou P. Understanding bone safety zones during bone marrow aspiration from the iliac crest: the sector rule. Int Orthop. 2014; 38(11):2377–2384.
Article
15. Hernigou J, Alves A, Homma Y, Guissou I, Hernigou P. Anatomy of the ilium for bone marrow aspiration: map of sectors and implication for safe trocar placement. Int Orthop. 2014; 38(12):2585–2590.
Article
16. Hernigou P, Poignard A, Zilber S, Rouard H. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop. 2009; 43(1):40–45.
Article
17. Gangji V, Hauzeur JP, Matos C, De Maertelaer V, Toungouz M, Lambermont M. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells: a pilot study. J Bone Joint Surg Am. 2004; 86(6):1153–1160.
Article
18. Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone. 2011; 49(5):1005–1009.
Article
19. Papakostidis C, Tosounidis TH, Jones E, Giannoudis PV. The role of "cell therapy" in osteonecrosis of the femoral head. Acta Orthop. 2016; 87(1):72–78.
Article
20. Hernigou P, Flouzat-Lachaniette CH, Delambre J, et al. Osteonecrosis repair with bone marrow cell therapies: state of the clinical art. Bone. 2015; 70:102–109.
Article
21. Kawate K, Yajima H, Ohgushi H, et al. Tissue-engineered approach for the treatment of steroid-induced osteonecrosis of the femoral head: transplantation of autologous mesenchymal stem cells cultured with beta-tricalcium phosphate ceramics and free vascularized fibula. Artif Organs. 2006; 30(12):960–962.
Article
22. Kang JS, Moon KH, Park SR, Kang SB, Park HB, Lee SH. Clinical results of autoiliac cancellous bone graft combined with implantation of autologous bone marrow cells for osteonecrosis of the femoral head. J Korean Orthop Assoc. 2008; 43(1):1–8.
Article
23. Liu L, Sun Z, Chen B, et al. Ex vivo expansion and in vivo infusion of bone marrow-derived Flk-1+CD31-CD34- mesenchymal stem cells: feasibility and safety from monkey to human. Stem Cells Dev. 2006; 15(3):349–357.
Article
24. Yan Z, Hang D, Guo C, Chen Z. Fate of mesenchymal stem cells transplanted to osteonecrosis of femoral head. J Orthop Res. 2009; 27(4):442–446.
Article
25. Yamasaki T, Yasunaga Y, Ishikawa M, Hamaki T, Ochi M. Bone-marrow-derived mononuclear cells with a porous hydroxyapatite scaffold for the treatment of osteonecrosis of the femoral head: a preliminary study. J Bone Joint Surg Br. 2010; 92(3):337–341.
26. Wang BL, Sun W, Shi ZC, et al. Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Arch Orthop Trauma Surg. 2010; 130(7):859–865.
Article
27. Rackwitz L, Eden L, Reppenhagen S, et al. Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head. Stem Cell Res Ther. 2012; 3(1):7.
Article
28. Zhao D, Cui D, Wang B, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. 2012; 50(1):325–330.
Article
29. Liu Y, Liu S, Su X. Core decompression and implantation of bone marrow mononuclear cells with porous hydroxylapatite composite filler for the treatment of osteonecrosis of the femoral head. Arch Orthop Trauma Surg. 2013; 133(1):125–133.
Article
30. Mao Q, Jin H, Liao F, Xiao L, Chen D, Tong P. The efficacy of targeted intraarterial delivery of concentrated autologous bone marrow containing mononuclear cells in the treatment of osteonecrosis of the femoral head: a five year follow-up study. Bone. 2013; 57(2):509–516.
Article
31. Hernigou P, Lambotte JC. Volumetric analysis of osteonecrosis of the femur: anatomical correlation using MRI. J Bone Joint Surg Br. 2001; 83(5):672–675.
32. Hernigou P, Lambotte JC. Bilateral hip osteonecrosis: influence of hip size on outcome. Ann Rheum Dis. 2000; 59(10):817–821.
Article
33. Homma Y, Kaneko K, Hernigou P. Supercharging allografts with mesenchymal stem cells in the operating room during hip revision. Int Orthop. 2014; 38(10):2033–2044.
Article
34. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595–610.
Article
35. Frost HM. Intermediary organization of the skeleton. Boca Raton: CRC Press;1986.
36. Jones EA, Yang XB. Mesenchymal stem cells and their future in bone repair. Int J Adv Rheumatol. 2005; 3(3):15–21.
37. Gangji V, Hauzeur JP. Cellular-based therapy for osteonecrosis. Orthop Clin North Am. 2009; 40(2):213–221.
Article
38. Poignard A, Lebouvier A, Cavet M, et al. New preclinical porcine model of femoral head osteonecrosis to test mesenchymal stromal cell efficiency in regenerative medicine. Int Orthop. 2014; 38(9):1837–1844.
Article
39. Leotot J, Lebouvier A, Hernigou P, Bierling P, Rouard H, Chevallier N. Bone-forming capacity and biodistribution of bone marrow-derived stromal cells directly loaded into scaffolds: a novel and easy approach for clinical application of bone regeneration. Cell Transplant. 2015; 24(10):1945–1955.
Article
40. Lebouvier A, Poignard A, Cavet M, et al. Development of a simple procedure for the treatment of femoral head osteonecrosis with intra-osseous injection of bone marrow mesenchymal stromal cells: study of their biodistribution in the early time points after injection. Stem Cell Res Ther. 2015; 6:68.
Article
41. Lebouvier A, Poignard A, Coquelin-Salsac L, et al. Autologous bone marrow stromal cells are promising candidates for cell therapy approaches to treat bone degeneration in sickle cell disease. Stem Cell Res. 2015; 15(3):584–594.
Article
42. Hernigou P, Bernaudin F, Reinert P, Kuentz M, Vernant JP. Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: a case report with a four-year follow-up. J Bone Joint Surg Am. 1997; 79(11):1726–1730.
43. Xiao ZM, Jiang H, Zhan XL, Wu ZG, Zhang XL. Treatment of osteonecrosis of femoral head with BMSCs-seeded bioderived bone materials combined with rhBMP-2 in rabbits. Chin J Traumatol. 2008; 11(3):165–170.
Article
44. Tang TT, Lu B, Yue B, et al. Treatment of osteonecrosis of the femoral head with hBMP-2-gene-modified tissue-engineered bone in goats. J Bone Joint Surg Br. 2007; 89(1):127–129.
Article
45. Wen Q, Ma L, Chen YP, Yang L, Luo W, Wang XN. Treatment of avascular necrosis of the femoral head by hepatocyte growth factor-transgenic bone marrow stromal stem cells. Gene Ther. 2008; 15(23):1523–1535.
Article
46. Hernigou P, Homma Y, Flouzat-Lachaniette CH, Poignard A, Chevallier N, Rouard H. Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate. J Bone Joint Surg Am. 2013; 95(24):2215–2221.
Article
47. Hernigou P, Flouzat Lachaniette CH, Delambre J, Chevallier N, Rouard H. Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence? Int Orthop. 2014; 38(9):1825–1835.
Article
Full Text Links
  • CIOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr